Research programme: carbon nanotube anticancer therapeutics - Ensysce Biosciences

Drug Profile

Research programme: carbon nanotube anticancer therapeutics - Ensysce Biosciences

Latest Information Update: 11 Jul 2015

Price : $50

At a glance

  • Originator Ensysce Biosciences
  • Class Doxorubicins; Paclitaxels; Small interfering RNA
  • Mechanism of Action DNA intercalators; Mitosis inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; RNA interference; Tubulin inhibitors; Tubulin polymerisation promoters; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 11 Jul 2015 Preclinical development is ongoing in USA
  • 25 Sep 2012 Ensysce Biosciences receives SBIR grant from the National Institutes of Health for the development of single walled carbon nanotubes for Cancer
  • 06 Jun 2012 Preclinical trials in Cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top